Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Core Viewpoint - Precision BioSciences, Inc. has received a Study May Proceed notification from the U.S. FDA, enabling the company to start clinical trial activities for its FUNCTION-DMD Phase 1/2 trial [1] Group 1 - The company specializes in gene editing using its proprietary ARCUS® platform to develop therapies for diseases with high unmet needs [1] - The FDA's notification allows Precision BioSciences to initiate Institutional Review Board (IRB) activities and activate clinical trial sites [1]